<DOC>
	<DOCNO>NCT02246920</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled , parallel group , multi-site study design compare safety efficacy generic Fluticasone propionate Nasal Spray , 50 mcg ( Teva Pharmaceuticals USA ) FDA Reference Listed Drug , FlonaseÂ® ( fluticasone propionate ) 50 mcg nasal spray ( GlaxoSmithKline ) , relief sign symptom Seasonal Allergic Rhinitis . Additionally , test reference formulation test superiority placebo nasal spray .</brief_summary>
	<brief_title>Clinical Equivalence Study Fluticasone Propionate Nasal Spray , 50 mcg/Actuation vs. Flonase Allergic Rhinitis Patients</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Male nonpregnant , nonlactating female 12 year age old . Signed informed consent form , meet criteria current FDA regulation . For patient age majority state study conduct ( 18 year state ) parent legal guardian sign consent form child require sign patient `` assent '' form write way understandable child . If female childbearing potential , negative urine pregnancy test prepare abstain sexual intercourse use reliable method contraception study . In order hormonal birth control consider reliable method patient must regimen least 28 day . Documented positive allergic skin test , perform within previous 12 month , one allergens season time study conduct . A minimum two consecutive year previous history seasonal allergic rhinitis pollen/allergen season time study conduct . A score least 6 reflective Total Nasal Symptom Score ( rTNSS ) minimum score least 2 `` nasal congestion '' minimum score least 2 one remain 3 symptom represent 12 hour prior screen visit . An average composite score least 6 reflective Total Nasal Symptom Score ( rTNSS ) minimum score least 2 `` nasal congestion '' minimum score least 2 one remain 3 symptom represent last 3 day 7day leadin period randomization visit morning first day randomization visit . Under 12 year age . Females pregnant , lactating , likely become pregnant study . Negative lack document skin allergen test ( perform within previous 12 month ) least one allergens season time study conduct . The result positive shin allergen test report . Patients suffer chronic sign symptom perennial allergic rhinitis ( PAR ) exclude study unless Investigator assess patient 's current sign symptom clear exacerbation Seasonal Allergic Rhinitis ( SAR ) rather chronic PAR . Patients suffer perennial allergic rhinitis seasonal allergic rhinitis different allergen season time study conduct . Previous history le 2 year seasonal allergic rhinitis pollen/allergen season time study conduct . A total score le 6 reflective Total Nasal Symptom Score ( rTNSS ) score less 2 `` nasal congestion '' score less 2 3 remain symptom . History asthma previous 2 year require chronic therapy . Occasional acute mild exercise induce asthma allowable condition treatment attack restrict betaagonists . Patients nasal condition , include infectious rhinitis , rhinitis medicamentosa , atrophic rhinitis . Clinically significant nasal deformity ( e.g . significantly deform septum , nasal polyp , ulcer ) recent nasal surgery trauma completely heal . Sinus infection within previous 30 day history reoccuring sinus infection . Patient start immunotherapy ( include topical desensitization therapy ) change dose immunotherapy within 30 day first dose , likely start immunotherapy , change current dose study . Treatment oral Candidiasis within 30 day start study current Candidiasis infection . Upper respiratory tract infection within previous 30 day . Patients history tuberculosis . Patients presence glaucoma , cataract , ocular herpes simplex , conjunctivitis , eye infection relate diagnosis SAR within 14 day enrollment . The patient recent exposure ( 30 day ) risk expose chicken pox measles . Patients untreated fungal , bacterial , systemic viral infection within previous 30 day . Use ophthalmic steroid within 14 day nasal , inhale , systemic steroid within 30 day study start . Use medication significantly inhibit cytochrome P450 subfamily enzyme CYP3A4 . Use intranasal systemic secondgeneration antihistamine within 10 day enrollment . Use intranasal cromolyn within 14 day enrollment . Use intranasal systemic firstgeneration antihistamine , leukotriene receptor antagonist nasal decongestant within 3 day enrollment . Use tricyclic antidepressant within 30 day enrollment . Patients attentiondeficit disorder treat methylphenidate containing product stable dose regimen least 30 previous day remain dosing regimen throughout study . Desensitization therapy seasonal allergen cause patient allergic rhinitis within previous 6 month . Previous SAR and/or PAR proven unresponsive steroid therapy . Any known hypersensitivity fluticasone , steroid , component study nasal spray . Significant history current evidence chronic infectious disease , system disorder , organ disorder , medical condition Investigator 's opinion would place study patient undue risk participating , could jeopardize integrity study evaluation . Receipt drug part research study within 30 day prior first dose . Planned travel outside local area 2 consecutive day 3 day total , patient 's participation study . Previous participation study . The patient history noncompliance medical regimen treatment protocols previous clinical study . The patient member investigational study staff member family investigational study staff . The patient currently smoke cigarette , cigar , and/or pipe heavy smoker ( example , average 10 cigarette per day ) .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Allergic Rhinitis</keyword>
</DOC>